

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/207150 A1

- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *C12N 5/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/025906
- (22) **International Filing Date:**
06 April 2021 (06.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/005,684 06 April 2020 (06.04.2020) US
- (71) **Applicant:** CELLEDIT LLC [US/US]; 100 Barber Avenue, Worcester, MA 01606 (US).
- (72) **Inventor:** HU, Biliang; c/o Celledit LLC, 100 Barber Avenue, Worcester, MA 01606 (US).
- (74) **Agent:** CHEN, Yahua; c/o McDermott Will & Emery LLP, 500 North Capitol Street, NW, Washington, DC 20001 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** GENETICALLY MODIFIED IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND HAVING REDUCED PROINFLAMMATORY CYTOKINE SIGNALING



(57) **Abstract:** A population of immune cells comprising modified immune cells co-expressing a chimeric antigen receptor comprising, inter alia, an IB-2K β cytoplasmic signaling domain. Also provided herein are genetically engineered immune cells having reduced production of interferon gamma (IFN γ). Such genetically engineered immune cells may have a disrupted endogenous IFN γ gene, a disrupted endogenous IFN γ receptor (IFN γ R) gene, or both. Alternatively, the immune cells may express an IFN γ antagonist.

WO 2021/207150 A1